Nissan Micra

St. Joseph's Children's Hospital First in Tampa Bay to Implant Leadless Pacemaker in Pediatric Heart Patient

Retrieved on: 
Friday, February 2, 2024
Partnership, Medicine, Ventricular septal defect, Leg, Life, Hospital, Child, Medtronic, Electrophysiology, Heart, Patient, Nissan Micra, Skin, Congenital heart block, Dizziness, Blood, Infection, Medical device

TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.

Key Points: 
  • TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.
  • The procedure was performed by Dr. Kelvin Lau, director of pediatric electrophysiology at St. Joseph's Children's Hospital, on a teenage girl who was born with isolated congenital heart block.
  • The Patel Children's Heart Institute at St. Joseph's Children's Hospital is home to the Tampa Bay area's only comprehensive congenital heart disease program.
  • A partnership between St. Joseph's Children's Hospital and UPMC Children's Hospital of Pittsburgh provides families across Florida with unprecedented access to the highest level of pediatric heart care available.

Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology

Retrieved on: 
Wednesday, October 25, 2023
NYHA, American College, Food, CRT, LVEF, Cardiac resynchronization therapy, Heel, McCutcheon, ASX, Achilles, Institutional review board, Coronary sinus, Wise, Journal, Cardiology, Patient, Food and Drug Administration, Heart failure, MD, Nissan Micra, JACC, Research, Growth, QRS, FDA, IRB, Cardiac electrophysiology, Journal of the American College of Cardiology, EBR, Medtronic, Failure, Medical device, Television, Pharmaceutical industry

The positive results published in JACC are based on a 1-year follow-up of the first-in-human implantation in the US of totally leadless CRT pacing utilizing the Micra™ leadless pacing system in the right ventricle in conjunction with EBR's investigational WiSE® CRT Electrode in the left ventricle of the heart.

Key Points: 
  • The positive results published in JACC are based on a 1-year follow-up of the first-in-human implantation in the US of totally leadless CRT pacing utilizing the Micra™ leadless pacing system in the right ventricle in conjunction with EBR's investigational WiSE® CRT Electrode in the left ventricle of the heart.
  • This first use in the US of the WiSE CRT System as a first-line therapy is a future market expansion opportunity for EBR.
  • "It's great to see these positive results being published in a world-leading cardiology journal, such as The Journal of the American College of Cardiology," said John McCutcheon, President & CEO of EBR Systems.
  • "This case study highlights the potential of totally leadless CRT for patients struggling with traditional CRT, but also beyond these patient groups, the 64 million heart failure patients across the globe."

Medtronic receives FDA approval for its next generation Micra leadless pacing systems

Retrieved on: 
Monday, May 1, 2023
Life, Comparable, Medtronic, Food and Drug Administration, Skin, Lead, MHS, VR2, Patient, Algorithm, Conductance quantum, FDA, NYSE, Food, Duke University Health System, Medical device, Nissan Micra

DUBLIN, May 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniaturized, leadless pacemakers.

Key Points: 
  • DUBLIN, May 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniaturized, leadless pacemakers.
  • Comparable in size to a multivitamin, Micra pacemakers are less than one-tenth the size of traditional pacemakers.
  • Leaders in Cardiac Pacing This FDA approval builds on the Medtronic legacy in cardiac pacing, which includes:
    Inventing the first wearable pacemaker in 1957.
  • Gaining regulatory approval for the first pacing system to activate the heart's natural electrical system, conduction system pacing (approval via the His-bundle in 2018 and via the left bundle branch area in 2022).

Nissan's e-4ORCE video shows how innovative automotive technology can get tails wagging

Retrieved on: 
Thursday, February 23, 2023
4WD, Motion sickness, Family, Dog, Ariya, Nissan X-Trail, Patient, Hiraku Nakajima, Pet, Nissan Ariya, Acceleration, Movement, Multimedia, EV, Cat, Automotive industry, Online shopping, Nissan, Nissan Micra

YOKOHAMA, Japan, Feb. 23, 2023 /PRNewswire/ -- Nissan today released a new video highlighting how e-4ORCE technology has the potential to reduce motion sickness for both people and their canine companions.

Key Points: 
  • Nissan's latest 4WD system manages the forces at each wheel through control of the brakes and twin high-output motors.
  • e-4ORCE can also calculate cornering loads in response to driver inputs and road conditions, then adjust the driving power of all four wheels.
  • From everyday conditions to winding or slippery roads, this unprecedented system provides a powerful, responsive experience in all types of driving.
  • For more information about our products, services and commitment to sustainable mobility, visit
    View original content to download multimedia: https://www.prnewswire.com/news-releases/nissans-e-4orce-video-shows-how...

Nissan's e-4ORCE video shows how innovative automotive technology can get tails wagging

Retrieved on: 
Thursday, February 23, 2023
4WD, Motion sickness, Family, Dog, Ariya, Nissan X-Trail, Patient, Hiraku Nakajima, Pet, Nissan Ariya, Acceleration, Movement, EV, Cat, Automotive industry, Nissan, Nissan Micra

YOKOHAMA, Japan, Feb. 23, 2023 /PRNewswire/ -- Nissan today released a new video highlighting how e-4ORCE technology has the potential to reduce motion sickness for both people and their canine companions.

Key Points: 
  • Nissan's latest 4WD system manages the forces at each wheel through control of the brakes and twin high-output motors.
  • By integrating 4WD control, chassis and electrification technologies, e-4ORCE can mitigate pitch and dive under acceleration and braking.
  • e-4ORCE can also calculate cornering loads in response to driver inputs and road conditions, then adjust the driving power of all four wheels.
  • From everyday conditions to winding or slippery roads, this unprecedented system provides a powerful, responsive experience in all types of driving.

Cardiac Pacemakers Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Tuesday, December 6, 2022
United Nations, Degenerative disease, Arrhythmia, Aortic valve, LivaNova, St. Jude Medical, Heart, Atrial fibrillation, Disorder, Medtronic, Long QT syndrome, CVD, Research report, Blood, Patient, Hospital, Nissan Micra, Incidence, World Health Organization, TPS, CNT, COVID-19, Ventricular septal defect, AV, Growth, Heart rate, Hypertension, Atrioventricular block, Boston Scientific, Cardiovascular disease, Cook Group, Organization, Medical device, Cordis

The cardiac pacemakers market is expected to grow to $4.91 billion in 2026 at a compound annual growth rate (CAGR) of 3.62%.

Key Points: 
  • The cardiac pacemakers market is expected to grow to $4.91 billion in 2026 at a compound annual growth rate (CAGR) of 3.62%.
  • The cardiac pacemakers market consists of sales of cardiac pacemaker devices by entities (organizations, sole traders, and partnerships) that are used to maintain the rhythm of heartbeats.
  • New innovations are a key trend in the cardiac pacemaker market.Major players are making innovations like leadless cardiac pacemakers to cater to the cardiac pacemaker market in a better way.
  • The cardiac pacemakers market research report is one of a series of new reports that provides cardiac pacemakers market statistics, including cardiac pacemakers industry global market size, regional shares, competitors with a cardiac pacemakers market share, detailed cardiac pacemakers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac pacemakers industry.

Medtronic First to Receive FDA Approval for Pacing the Heart's Natural Conduction System

Retrieved on: 
Monday, October 17, 2022
Physician, LinkedIn, U.S. Securities and Exchange Commission, 3830, NYSE, Bradycardia, Patient, AV, SK, Twitter, Security (finance), Elbogen, MDT, Electrophysiology, Food, Systematic review, Food and Drug Administration, Health, Nissan Micra, Pain, Atrioventricular block, Wilkes-Barre, Pennsylvania, Meta-analysis, FDA, Solution, Medical device, Medical imaging, Medtronic

DUBLIN, Oct. 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, giving patients needed therapy while avoiding complications sometimes associated with traditional pacing methods, such as cardiomyopathy.1 Commonly referred to as "conduction system pacing," this approach helps ensure that pacing closely mimics the heart's physiologic contractions, allowing the heart's ventricles to work in coordination.1

Key Points: 
  • In 2018, the FDA approved the SelectSecure MRI SureScan Model 3830 cardiac lead for His-Bundle pacing, another form of conduction system pacing.
  • Now this cardiac lead is approved for pacing and sensing at the bundle of His or in the left bundle branch area as an alternative to apical pacing in the right ventricle in a single- or dual-chamber pacing system.
  • This new approval adds to the Medtronic legacy of cardiac pacing innovative "firsts," which include:
    The first leadless pacemaker (the Micra Transcatheter Pacing System, launched in 2016 and expanded to patients with AV block in 2020)
    The first wearable pacemaker invented by Medtronic founder Earl Bakken in 1957.
  • "Expanded labeling of this lead allows us to train physicians to successfully perform left bundle procedures, bringing the benefits of conduction system pacing to more patients."

Medtronic appoints new Operating Unit Presidents

Retrieved on: 
Thursday, March 17, 2022
Twitter, Honeywell, Solution, Microsoft, SVP, Technology, Acquisition, Cardiac resynchronization therapy, Arrhythmia, U.S. Securities and Exchange Commission, Health, Sofie (surgical robot), McKinsey & Company, Pain, Data science, Connected space, Security (finance), Nissan Micra, Artificial intelligence, Family, Digital, Leadership, CEO, Hugo, Growth, Dallara, EVP, NYSE, TE, Industry, Robotics, Medical-surgical nursing, LinkedIn, Diabetes, Dentistry, Medical device, Management, Medtronic, Salmon

Que Dallara joins as Executive Vice President and Operating Unit President, Diabetes

Key Points: 
  • Que Dallara joins as Executive Vice President and Operating Unit President, Diabetes
    Que Dallara joins the Medtronic Executive Committee reporting to Chairman and CEO Geoff Martha on May 2, 2022.
  • Mike Marinaro named Operating Unit President, Surgical Robotics
    Marinaro joins the Medical Surgical Portfolio leadership team reporting to Executive Vice President and President, Bob White.
  • Dr. Kweli Thompson named Operating Unit President, Cardiac Rhythm Management
    Dr. Thompson joins the Cardiovascular Portfolio leadership team reporting to Salmon.
  • For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com ,and follow @Medtronic on Twitter and LinkedIn .

Renault, Nissan & Mitsubishi Motors Announce Common Roadmap Alliance 2030: Best of 3 Worlds for a New Future

Retrieved on: 
Friday, January 28, 2022
Cloud, Family, PARIS, ICE, Solution, Kilowatt-hour, Software, Nissan Micra, Mitsubishi Motors, Jean-Dominique Senard, OEM, Mitsubishi, Intelligence, Outlander, Alpine, Technology, Recycling, Carbon, Nissan Ariya, Connected, IONITY, R5, Renault 5, Health, Renault Kangoo, Atmosphere of Earth, EUR, Electricity, EV, Nissan Qashqai, Google, Investment, Industry, Electronics, New, Element, Competition (economics), EVS, Parity, Maintenance, Motor vehicle, Fireworks, Medical device, Video game console, Mobile phone, Electric battery, Network equipment, Nissan, Alliance, ADAS

The Alliance has defined a common 2030 roadmap on pure-EV and Intelligent & Connected mobility, sharing investments for the benefits of its three-member companies and their customers.

Key Points: 
  • The Alliance has defined a common 2030 roadmap on pure-EV and Intelligent & Connected mobility, sharing investments for the benefits of its three-member companies and their customers.
  • The three member-companies have defined a common roadmap towards 2030, sharing investments in future electrification and connectivity projects.
  • Together, we are making the difference for a new and global sustainable future; the Alliance becoming carbon neutral by 2050."
  • with Renault Group, Nissan Motor Co., Ltd and Mitsubishi Motors positioned at the forefront of this revolution.

Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System

Retrieved on: 
Monday, January 10, 2022
Ministry, CE marking, Patient, Technology, LinkedIn, AV, Algorithm, U.S. FDA, Miniaturization, Purkinje fibers, NYSE, Safety, Premature atrial contraction, Solution, MARVEL, U.S. Securities and Exchange Commission, History, Skin, Pain, Nissan Micra, Heart, MRI, Atrioventricular block, Sale, TPS, Twitter, FDA, Security (finance), Physician, List of health departments and ministries, Medical device, Medtronic, Health

The Micra TPS is the first-ever leadless pacemaker; its first version (the Micra VR) was approved in Japan in 2017 for patients who only require single-chamber pacing.

Key Points: 
  • The Micra TPS is the first-ever leadless pacemaker; its first version (the Micra VR) was approved in Japan in 2017 for patients who only require single-chamber pacing.
  • "The first Micra system transformed the concept of pacemakers by eliminating surgical pockets and leads, and Micra AV promises to deliver the benefits of leadless pacing to a larger number of patients because ventricular pacing can be performed synchronously with the atrium."
  • Identical in size and shape to the original Micra TPS, Micra AV has several additional algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing "AV synchronous" pacing therapy to patients with AV block.
  • The Micra AV approval is based on data from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, which evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms.